Dianthus therapeutics highlights recent business achievements and reports q2 financial results

Phase 2 magic trial in generalized myasthenia gravis (gmg) ongoing;  top-line results anticipated in 2h'25 ind for phase 2 momentum trial in multifocal motor neuropathy (mmn) cleared by fda in june;  top-line results anticipated in 2h'26 phase 2 trial in chronic inflammatory demyelinating polyneuropathy (cidp) to initiate 2h'24  approximately $361 million of cash provides runway into 2h'27 new york and waltham, mass., aug. 08, 2024 (globe newswire) -- dianthus therapeutics, inc. (nasdaq: dnth), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune diseases, today reported financial results for the second quarter ending june 30, 2024, and provided an update on recent business achievements.
DNTH Ratings Summary
DNTH Quant Ranking